David A. Spellman - 08 Jun 2022 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role: SVP, CFO and Treasurer
Signature: /s/ Carolyn Rucci, attorney-in-fact for David A. Spellman
Issuer symbol: AKBA
Transactions as of: 08 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 10 Jun 2022, 08:11:54 UTC
Previous filing: 02 Mar 2022
Next filing: 02 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKBA	Common Stock	Award	$0	+200,000	+156%	$0.000000	328,599	08 Jun 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKBA	Stock Option (Right to buy)	Award	$0	+200,000		$0.000000	200,000	08 Jun 2022	Common Stock	200,000	$0.4500	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"). The RSUs will vest in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date.
F2	The option to purchase shares of the Issuer's common stock ("the Stock Option") was granted by the Issuer pursuant to the 2014 Plan. The Stock Option will vest and become exercisable in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date.